The Patent Finder

Beta-D-2'-Deoxy-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT

Atea Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 9 of these applications claim priority to application 62/129,319, filed Mar 6, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,828,410Beta-D-2'-Deoxy-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 10,000,523BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 10,005,811BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 10,239,911BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 10,815,266BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 10,870,672Beta-D-2'-Deoxy-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 10,870,673BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 10,875,885BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
In force
 · High confidence
Atea Pharmaceuticals, Inc.In force
High confidence
US 12,084,473BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
In force
 · Low confidence
Atea Pharmaceuticals, Inc.In force
Low confidence
Application 17/028,724Beta-D-2'-Deoxy-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
Abandoned
Abandoned Apr 9, 2022
Atea Pharmaceuticals, Inc.AbandonedAbandoned Apr 9, 2022
2 more patents in this group · Pro
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12.
Upgrade to Pro
9 of these are in force and held by Atea Pharmaceuticals, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited